Abstract 2424
Background
Prognosis of metastatic pancreatic adenocarcinoma is gloomy. To elicit a chemotherapy regimen with higher efficiency and with lower toxicities is critical important.
Methods
This was a one arm, phase 2, three-center study. Enrolled patients were histological or pathologically confirmed; treatment naïve metastatic pancreatic adenocarcinoma. Enrolled patients were 18 years or older, with at least one measurable lesion and performance status between 0-2 with ECOG score. Irrinotecan 165 mg/m2 and oxaliplatin 85 mg/m2 were administered intravenous infusion on days 1, and S1 40 mg/m2 was administered orally on day 1-14, every 21 day a cycle until progressive disease or intolerable toxicities or patient death. The primary endpoint was overall survival and the second endpoints were progression-free survival and toxicities.
Results
A total of 41 patients were enrolled, median age was 59 year-old. There were 18 men and 23 women. The median progression-free survival was 4.33 (95% CI: 2.83-5.88) and median overall survival was 11.00 (95% CI: 9.16-12.84). There were 38 patients validated for efficiency evaluation. There was no complete response, the partial response rate, stable disease and progression disease was 42.11% (16/38), 31.58% (12/38) and 26.32% (10/38) respectively. The most common adverse effect was mild to moderate nausea, vomiting, neutropenia and thrombocytopenia. The 3/4 degree neutropenia and thrombocytopenia were 29.27% (12/41) and 12.20% (5/41) respectively.
Conclusions
Irinotecan combined with oxaliplatin and S1 was effective in metastatic pancreatic adenocarcinoma; its toxicities were mild to moderate and tolerable. Furthermore, patients to enrol the study is needed.
Clinical trial identification
NCT03726021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2551 - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.
Presenter: Benedetta Conte
Session: Poster Display session 2
Resources:
Abstract
3426 - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).
Presenter: Sonja Vliek
Session: Poster Display session 2
Resources:
Abstract
3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Presenter: Gustavo Werutsky
Session: Poster Display session 2
Resources:
Abstract
4044 - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.
Presenter: Mark De Ridder
Session: Poster Display session 2
Resources:
Abstract
719 - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Presenter: Justin Stebbing
Session: Poster Display session 2
Resources:
Abstract
3595 - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival
Presenter: Axel Berthelot
Session: Poster Display session 2
Resources:
Abstract
3992 - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.
Presenter: Maria Vittoria Dieci
Session: Poster Display session 2
Resources:
Abstract
3477 - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Presenter: Mellissa Williamson
Session: Poster Display session 2
Resources:
Abstract
3928 - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Presenter: Hans Tesch
Session: Poster Display session 2
Resources:
Abstract
2184 - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract